CA 19-9 ELISA Kit

Produktnummer ABIN996902

Produktdetails CA 19-9 ELISA Kit

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 0-240 U/mL

Untere Nachweisgrenze: 0 U/mL

Applikation: ELISA

Verwendungszweck: The CA19-9 assay kit is intended to be used as a monitoring and screening test.

Proben: Serum

Analytische Methode: Quantitative

Spezifität: 97 %

Sensitivität: 5 U/mL

Anwendungsinformationen

Probenmenge: 50 μL

Testdauer: 2 - 3 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 12-14 months

Details zu CA 19-9

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Andere Bezeichnung: CA 19-9 (CA 19-9 Produkte)

Hintergrund: A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recent reports indicate that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA19-9 values may have utility in monitoring subjects with the above-mentioned diagnosed malignancies. It has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of occult metastatic and/or residual disease.

A persistently rising serum CA19-9 value may be associated with progressive malignant disease and poor therapeutic response. A declining CA19-9 value may be indicative of a favorable prognosis and good response to treatment. Test Principle The CA19-9 EIA test is a solid phase two-site immunoassay. One monoclonal antibody is coated on the surface of the microtiter wells and another monoclonal antibody labeled with horseradish peroxidase is used as the tracer. The CA19-9 molecules present in the standard solution or serum are sandwiched between the two antibodies. Following the formation of the coated antibody-antigen-antibody-enzyme complex, the unbound antibody-enzyme labels are removed by washing. The horseradish peroxidase activity bound in the wells is then assayed by colorimetric reactions. The intensity of the color formed is proportional to the concentration of CA19-9 present in the sample.